Astellas Signs Distribution Agreement With Tecnofarma For Enzalutamide In Latin America

Astellas Pharma US, Inc,  a subsidiary of Tokyo-based Astellas Pharma Inc. has entered into a distribution agreement with Tecnofarma International Ltd. to distribute enzalutamide (XTANDI^® in the U.S.)  in Latin America, excluding Brazil, upon regulatory approvals in the various countries. Financial terms of the agreements were not disclosed.
Astellas already has an agreement with Tecnofarma, for distribution of Mycamine® in Latin America. Tecnofarma has a strong Latin American sales and marketing oncology organization.

Otsuka Pharmaceutical Factory and Fresenius Kabi Japan enter into an exclusive distribution agreement of HES products, including the newly approved Voluven 6%

Otsuka Pharmaceutical Factory, Inc.  and Fresenius Kabi Japan (FKJ) have entered into an exclusive distribution agreement in Japan, of Voluven 6%, a new to be launched HES (Hydroxyethl Starch) product, (approved on March 25, 2013) and two other existing HES products, Salinhes Fluid Solution 6% and Hespander Fluid Solution. The two products on the market are currently sold by FKJ.